BCYC

SEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 1

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33651 to GBP 1.00 as of November 23, 2020.

SEC source: 0001209191-20-048252 · doc4.xml · derivative · entry 1

Smethurst Dominic · CIK 0001820549 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Ordinary Shares · 120,000 shares

Expires 2030-08-21

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on August 10, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001387131-20-008376 · bcyc-form4_071420.xml · nonDerivative · entry 3

GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,910,531

F1 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0001387131-20-008376 · bcyc-form4_071420.xml · nonDerivative · entry 2

GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,910,609

F1 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0001387131-20-008376 · bcyc-form4_071420.xml · nonDerivative · entry 1

GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,913,678

F1 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0001209191-20-024640 · doc4.xml · derivative · entry 2

Winter Gregory Paul · CIK 0001777021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,450

Underlying: Ordinary Shares · 71,450 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Warrants to purchase Series A Preferred Shares had an exercise price of a nominal value per Series A Preferred Share, and, following Bicycle Therapeutics plc's initial public offering, became exercisable for ordinary shares. The Warrants are immediately exercisable and expire on May 26, 2027.

F1 · derivative.exercise_date: The Warrants to purchase Series A Preferred Shares had an exercise price of a nominal value per Series A Preferred Share, and, following Bicycle Therapeutics plc's initial public offering, became exercisable for ordinary shares. The Warrants are immediately exercisable and expire on May 26, 2027.

F1 · derivative.expiration_date: The Warrants to purchase Series A Preferred Shares had an exercise price of a nominal value per Series A Preferred Share, and, following Bicycle Therapeutics plc's initial public offering, became exercisable for ordinary shares. The Warrants are immediately exercisable and expire on May 26, 2027.

SEC source: 0001209191-20-024640 · doc4.xml · nonDerivative · entry 1

Winter Gregory Paul · CIK 0001777021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Warrants to purchase Series A Preferred Shares had an exercise price of a nominal value per Series A Preferred Share, and, following Bicycle Therapeutics plc's initial public offering, became exercisable for ordinary shares. The Warrants are immediately exercisable and expire on May 26, 2027.

SEC source: 0001209191-20-012510 · doc4.xml · derivative · entry 1

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,757

Underlying: Common Stock · 44,757 shares

Expires 2030-02-21

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001209191-20-001921 · doc4.xml · derivative · entry 2

Bourque Janice · CIK 0001783330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,202

Underlying: Ordinary Shares · 8,202 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following July 18, 2019.

SEC source: 0001209191-20-001921 · doc4.xml · derivative · entry 1

Bourque Janice · CIK 0001783330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Ordinary Shares · 16,000 shares

Expires 2030-01-02

SEC source: 0001209191-20-001990 · doc4.xml · derivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Ordinary Shares · 210,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter.

SEC source: 0001209191-20-001944 · doc4.xml · derivative · entry 1

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Ordinary Shares · 60,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter.

SEC source: 0001209191-20-001967 · doc4.xml · derivative · entry 1

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Ordinary Shares · 60,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter.

SEC source: 0001209191-20-001917 · doc4.xml · derivative · entry 1

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Ordinary Shares · 16,000 shares

Expires 2030-01-02

SEC source: 0001209191-20-001930 · doc4.xml · derivative · entry 1

Jordan Veronica GH · CIK 0001381123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Ordinary Shares · 16,000 shares

Expires 2030-01-02

SEC source: 0001209191-20-002011 · doc4.xml · derivative · entry 2

Kender Richard N · CIK 0001381205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,202

Underlying: Ordinary Shares · 8,202 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following July 18, 2019.

SEC source: 0001209191-20-002011 · doc4.xml · derivative · entry 1

Kender Richard N · CIK 0001381205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Ordinary Shares · 16,000 shares

Expires 2030-01-02

SEC source: 0001209191-20-002019 · doc4.xml · derivative · entry 1

Legault Pierre · CIK 0001391045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Ordinary Shares · 32,000 shares

Expires 2030-01-02

SEC source: 0001209191-20-001925 · doc4.xml · derivative · entry 1

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Ordinary Shares · 60,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter.

SEC source: 0001209191-20-001981 · doc4.xml · derivative · entry 1

Skynner Michael · CIK 0001776582 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Ordinary Shares · 60,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter.

SEC source: 0001209191-20-002003 · doc4.xml · derivative · entry 1

Winter Gregory Paul · CIK 0001777021 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Ordinary Shares · 16,000 shares

Expires 2030-01-02

SEC source: 0001209191-19-061400 · doc4.xml · derivative · entry 1

Jordan Veronica GH · CIK 0001381123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Ordinary Shares · 32,000 shares

Expires 2029-12-17

F1 · derivative.exercise_date: The shares underlying this option shall vest in 36 equal monthly installments at the end of each calendar month, commencing on October 23, 2019.

SEC source: 0001209191-19-051098 · doc4.xml · derivative · entry 1

Bourque Janice · CIK 0001783330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,798

Underlying: Ordinary Shares · 23,798 shares

Expires 2029-09-26

F1 · derivative.exercise_date: The shares underlying this option shall vest in 36 equal monthly installments commencing on July 18, 2019.

SEC source: 0001209191-19-051101 · doc4.xml · derivative · entry 1

Kender Richard N · CIK 0001381205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,798

Underlying: Ordinary Shares · 23,798 shares

Expires 2029-09-26

F1 · derivative.exercise_date: The shares underlying this option shall vest in 36 equal monthly installments commencing on July 18, 2019.

SEC source: 0001209191-19-051100 · doc4.xml · derivative · entry 1

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,174

Underlying: Ordinary Shares · 152,174 shares

Expires 2029-09-26

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments.

SEC source: 0001209191-20-001912 · doc4a.xml · derivative · entry 1

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,417

Underlying: Ordinary Shares · 107,417 shares

Expires 2029-09-26

F1 · shares: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error.

F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments.

F1 · derivative.underlying_shares: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error.

F1 · balance_after: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error.

SEC source: 0001209191-20-025811 · doc4a.xml · derivative · entry 1

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,404

Underlying: Ordinary Shares · 177,404 shares

Expires 2029-06-28

F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

SEC source: 0001209191-20-025816 · doc4a.xml · derivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,252

Underlying: Ordinary Shares · 506,252 shares

Expires 2029-06-28

F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

SEC source: 0001209191-20-025812 · doc4a.xml · derivative · entry 1

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,414

Underlying: Ordinary Shares · 283,414 shares

Expires 2029-06-28

F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

SEC source: 0001209191-20-025817 · doc4a.xml · derivative · entry 1

Legault Pierre · CIK 0001391045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,827

Underlying: Ordinary Shares · 116,827 shares

Expires 2029-06-28

F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

SEC source: 0001209191-20-025813 · doc4a.xml · derivative · entry 1

Skynner Michael · CIK 0001776582 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,895

Underlying: Ordinary Shares · 183,895 shares

Expires 2029-06-28

F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates.

SEC source: 0001104659-19-033169 · a4.xml · nonDerivative · entry 4

Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,751,437

SEC source: 0001104659-19-032920 · a4.xml · derivative · entry 7

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 636,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001104659-19-032920 · a4.xml · derivative · entry 6

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 71,450 shares

Expires not disclosed

F2 · security: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.underlying: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001104659-19-032920 · a4.xml · derivative · entry 5

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 893,195 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001104659-19-032920 · a4.xml · nonDerivative · entry 4

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,769,641

SEC source: 0001104659-19-032920 · a4.xml · nonDerivative · entry 3

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,601,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001104659-19-032920 · a4.xml · nonDerivative · entry 2

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 964,645

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001104659-19-032920 · a4.xml · nonDerivative · entry 1

Novartis Bioventures Ltd · CIK 0001297709 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 893,195

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0000903423-19-000235 · glaxo.xml · derivative · entry 5

GLAXOSMITHKLINE PLC · CIK 0001131399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 636,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0000903423-19-000235 · glaxo.xml · derivative · entry 4

GLAXOSMITHKLINE PLC · CIK 0001131399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 893,195 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0000903423-19-000235 · glaxo.xml · nonDerivative · entry 3

GLAXOSMITHKLINE PLC · CIK 0001131399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,915,275

F1 · shares: S.R. One, Limited acquired 385,714 Common Stock of Bicycle Therapeutics Limited (the "Issuer") in connection with the Issuer's initial public offering.

F3 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0000903423-19-000235 · glaxo.xml · nonDerivative · entry 2

GLAXOSMITHKLINE PLC · CIK 0001131399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,529,561

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0000903423-19-000235 · glaxo.xml · nonDerivative · entry 1

GLAXOSMITHKLINE PLC · CIK 0001131399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 893,195

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

SEC source: 0001104659-19-032907 · a4.xml · derivative · entry 1

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,404

Underlying: Ordinary Shares · 177,404 shares

Expires 2029-05-28

F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001104659-19-032912 · a4.xml · derivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,252

Underlying: Ordinary Shares · 506,252 shares

Expires 2029-05-28

F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001104659-19-032910 · a4.xml · derivative · entry 1

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,414

Underlying: Ordinary Shares · 283,414 shares

Expires 2029-05-28

F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001104659-19-032917 · a4.xml · derivative · entry 10

SVLSF V, LLC · CIK 0001644160 · 10% owner

SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner

SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner

SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P.

Disclosed balance after: 0

Underlying: Ordinary Shares · 13,169 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein

SEC source: 0001104659-19-032917 · a4.xml · derivative · entry 9

SVLSF V, LLC · CIK 0001644160 · 10% owner

SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner

SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner

SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P.

Disclosed balance after: 0

Underlying: Ordinary Shares · 18,485 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein

SEC source: 0001104659-19-032917 · a4.xml · derivative · entry 8

SVLSF V, LLC · CIK 0001644160 · 10% owner

SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner

SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner

SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V, L.P.

Disclosed balance after: 0

Underlying: Ordinary Shares · 623,196 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.underlying: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.